SCHEMBL4677550

SCHEMBL4677550

O=C(Cc1occc1Cc1ccccc1F)C(=O)c1nn[nH]n1

nearest known ligand 0.34

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MPO P05164 1/20 0.34
PTGDR2 Q9Y5Y4 1/20 0.34
CES1 P23141 1/20 0.33
NCEH1 Q6PIU2 1/20 0.33
ALDH1A1 P00352 3/20 0.32
MAPT P10636 1/20 0.32
HPGD P15428 1/20 0.32
TSHR P16473 1/20 0.32
AR P10275 1/20 0.32
L3MBTL1 Q9Y468 1/20 0.32
ERCC5 P28715 1/20 0.32
FEN1 P39748 1/20 0.32
CXCR3 P49682 3/20 0.32
MMEL1 Q495T6 1/20 0.31
ACHE P22303 1/20 0.31
NPC1 O15118 1/20 0.30
RAB9A P51151 1/20 0.30
HTT P42858 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4675795 0.91 PTGDR2 (0.34) MPOPTGDR2CES1NCEH1ALDH1A1
SCHEMBL4676202 0.85 CES1 (0.42) MPOCES1NCEH1ALDH1A1L3MBTL1
SCHEMBL4676124 0.83 MPO (0.33) MPOPTGDR2CES1NCEH1MAPT
SCHEMBL4677073 0.83 ALDH1A1 (0.32) MPOALDH1A1MAPTHPGDTSHR
SCHEMBL4670733 0.82 AR (0.36) MPOPTGDR2CES1NCEH1ALDH1A1
SCHEMBL4676361 0.82 PTGDR2 (0.35) MPOPTGDR2CES1NCEH1ALDH1A1
SCHEMBL4675013 0.82 FFAR2 (0.39) MPOPTGDR2CES1NCEH1MAPT
SCHEMBL4677164 0.82 PTGDR2 (0.38) MPOPTGDR2CES1NCEH1ALDH1A1
SCHEMBL4676492 0.82 L3MBTL1 (0.33) CES1NCEH1ALDH1A1MAPTTSHR
SCHEMBL4673351 0.80 CYP17A1 (0.33) CES1NCEH1NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1142872-B1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO (JP) 2008-10-15 EP disclosed
US-7098201-B2 Heteroaromatic derivatives having an inhibitory activity against HIV integrase SHIONOGI & CO., LTD. (JP) 2006-08-29 US disclosed
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase FUJISHITA TOSHIO (JP) 2004-01-01 US disclosed
US-6645956-B1 1-(5-(4-fluorobenzyl)furan-2-yl)-3-hydroxy-3-(1H-1,2,4-triazol-3 -yl)-propenone; viricides; AIDS treatment SHIONOGI & CO., LTD. (JP) 2003-11-11 US disclosed
US-6620841-B1 Furan or benzofuran derivatives substituted with triazole; acquired immunodeficiency syndrome (AIDS) SHIONOGI & CO., LTD. (JP) 2003-09-16 US disclosed
CN-1335834-A Aromatic heterocyclic compounds having HIV integrase inhibitory activity SHIONOGI & CO (JP) 2002-02-13 CN disclosed
EP-1142872-A1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO., LTD. (JP) 2001-10-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase RCOR1, BCOR, CYP8B1 MPO 4231/4885PTGDR2 4591/4885CES1 445/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.